Appetite downer awaits approval.
Wadman
Meredith
M
D001066:Appetite / Q000187:drug effects; D001067:Appetite Depressants / Q000009:adverse effects / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics / Q000639:trends; D005060:Europe; D005602:France; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000191:economics / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use; D011720:Pyrazoles / Q000191:economics / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use; D000077285:Rimonabant; D014481:United States; D014486:United States Food and Drug Administration; D015431:Weight Loss / Q000187:drug effects
D001067:Appetite Depressants; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant